1. Home
  2. SDGR vs VOR Comparison

SDGR vs VOR Comparison

Compare SDGR & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDGR

Schrodinger Inc.

N/A

Current Price

$19.99

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

N/A

Current Price

$120.05

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SDGR
VOR
Founded
1990
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.4B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
SDGR
VOR
Price
$19.99
$120.05
Analyst Decision
Buy
Buy
Analyst Count
9
10
Target Price
$21.00
$45.33
AVG Volume (30 Days)
1.1M
773.6K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
45.14
N/A
EPS
N/A
N/A
Revenue
$255,869,000.00
N/A
Revenue This Year
$0.76
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.29
N/A
52 Week Low
$10.95
$1.90
52 Week High
$23.02
$49.95

Technical Indicators

Market Signals
Indicator
SDGR
VOR
Relative Strength Index (RSI) 61.17 60.10
Support Level $17.23 $21.75
Resistance Level $19.42 $24.34
Average True Range (ATR) 0.85 1.13
MACD 0.09 -0.18
Stochastic Oscillator 53.16 54.84

Price Performance

Historical Comparison
SDGR
VOR

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: